Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher E Barbieri

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 24, 2017
Vasectomy and Risk of Prostate Cancer in a Screening TrialJonathan Shoag, Oleksander Savenkov, Paul J Christos, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
European Urology Open Science|December 10, 2020
Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular SubtypesSalma Ben-Salem, Qiang Hu, Yang Liu, et al.
Urologic Oncology|April 30, 2022
A multidisciplinary approach to optimize primary prostate cancer biobankingPeter Y Cai, Muhammad Asad, Michael A Augello, et al.
Cancer Discovery|June 13, 2025
Germline-somatic liaison dictates cancer subtype via de novo steroid biosynthesisPaola Gasperini, Alessandro Alaimo, Blerta Stringa, et al.
Cancer Cell|March 16, 2017
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR SignalingMirjam Blattner, Deli Liu, Brian D Robinson, et al.
Nature|September 8, 2020
Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypesElizabeth J Adams, Wouter R Karthaus, Elizabeth Hoover, et al.
Cell Reports|September 8, 2021
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivityIvana Grbesa, Michael A Augello, Deli Liu, et al.
Nature|June 28, 2019
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypesElizabeth J Adams, Wouter R Karthaus, Elizabeth Hoover, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
NEJM Evidence|June 20, 2022
Harm-to-Benefit of Three Decades of Prostate Cancer Screening in Black MenSpyridon P Basourakos, Roman Gulati, Randy A Vince, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 24, 2017
Vasectomy and Risk of Prostate Cancer in a Screening TrialJonathan Shoag, Oleksander Savenkov, Paul J Christos, et al.
BMC Cancer|August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
European Urology Open Science|December 10, 2020
Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular SubtypesSalma Ben-Salem, Qiang Hu, Yang Liu, et al.
Urologic Oncology|April 30, 2022
A multidisciplinary approach to optimize primary prostate cancer biobankingPeter Y Cai, Muhammad Asad, Michael A Augello, et al.
Cancer Discovery|June 13, 2025
Germline-somatic liaison dictates cancer subtype via de novo steroid biosynthesisPaola Gasperini, Alessandro Alaimo, Blerta Stringa, et al.
Cancer Cell|March 16, 2017
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR SignalingMirjam Blattner, Deli Liu, Brian D Robinson, et al.
Nature|September 8, 2020
Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypesElizabeth J Adams, Wouter R Karthaus, Elizabeth Hoover, et al.
Cell Reports|September 8, 2021
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivityIvana Grbesa, Michael A Augello, Deli Liu, et al.
Nature|June 28, 2019
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypesElizabeth J Adams, Wouter R Karthaus, Elizabeth Hoover, et al.
Pageof 11